NCT05366192View on ClinicalTrials.gov

The Safety of Paxlovid in Hemodialysis Patients With Covid-19

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

June 6, 2022

Study Completion Date

June 8, 2022

Conditions
Safety Issues
Interventions
DRUG

Nirmatrelvir and ritonavir stage 1

Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.

DRUG

Nirmatrelvir and ritonavir stage 2

Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.

Trial Locations (1)

200127

Department of Nephrology, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER